Table 2.
Reccurence-free survival | Overall survival | |||||||
---|---|---|---|---|---|---|---|---|
Variable | Univariate | Multivariate | Univariate | Multivariate | ||||
P value | HR | 95% CI | P value | P value | HR | 95% CI | P value | |
Age (≥60 years vs. <60 years) | 0.620 | 1.32 | 0.54–4.26 | 0.516 | 0.140 | 1.59 | 0.57–4.51 | 0.361 |
Sex (male vs. female) | 0.831 | 1.07 | 0.35–3.32 | 0.979 | 0.441 | 1.17 | 0.31–4.40 | 0.890 |
Nuclear grade (G3/4 vs. G1/2) | 0.018 | 1.92 | 0.58–6.33 | 0.209 | <0.001 | 3.08 | 0.92–10.28 | 0.060 |
Pathological T stage (pT3/4 vs. pT1/2) | <0.001 | 5.03 | 2.06–12.24 | <0.001 | <0.001 | 3.68 | 1.14–11.84 | 0.029 |
Tumour size (≥40 mm vs. <40 mm) | 0.007 | 2.67 | 1.16–6.19 | 0.021 | 0.005 | 6.67 | 1.51–29.40 | 0.012 |
Venous invasion (positive vs. negative) | <0.001 | 2.15 | 0.73–6.39 | 0.109 | <0.001 | 5.86 | 1.80–19.22 | 0.003 |
LncRNA risk group (high vs. low & intermediate) | 0.001 | 3.97 | 1.45–10.89 | 0.007 | 0.022 | 4.32 | 1.24–15.08 | 0.026 |